---
schema_version: "secwatch.filing_event.v1"
accession: "0001711279-23-000025"
form_type: "8-K"
ticker: "KRYS"
cik: "0001711279"
company_name: "Krystal Biotech, Inc."
filed_at: "2023-04-24T23:59:59+00:00"
generated_at: "2026-06-16T19:06:35.433416+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Krystal Biotech reports positive ocular data from compassionate use of B-VEC in DEB patient

## Summary
- Topical B-VEC achieved full corneal healing by 3 months and improved visual acuity from hand motion to 20/40 at 7 months.
- No drug-related adverse events observed; treatment was well tolerated in the patient.
- Patient had recurrent cicatrizing conjunctivitis; ocular complications affect >50% of recessive DEB patients.
- Company plans to engage regulators to expand B-VEC utility for ocular DEB manifestations.
- Ongoing preclinical studies evaluating intravitreal and subretinal deliveries for other ocular diseases.

## SEC filing metadata
- accession: 0001711279-23-000025
- form_type: 8-K
- ticker: KRYS
- cik: 0001711279
- company_name: Krystal Biotech, Inc.
- filed_at: 2023-04-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711279/000171127923000025/0001711279-23-000025-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711279/000171127923000025/krys-20230423.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001711279-23-000025
- JSON: https://secwatch.observer/filing/0001711279-23-000025.json
- Plain text: https://secwatch.observer/filing/0001711279-23-000025.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.